(MedPage Today) — For respiratory syncytial virus (RSV) prevention, the long-acting monoclonal antibody clesrovimab (Enflonsia) was well tolerated among infants at increased risk for severe disease through two RSV seasons, a randomized clinical…
Source: MedPage Today — Headlines
